To include your compound in the COVID-19 Resource Center, submit it here.

FoRx: A broader look at DNA damage repair

FoRx is using synthetic lethality to attack a broad set of cancers with new DNA damage repair targets

University of Geneva spinout FoRx debuted this week with €10 million in seed funding, a trio of strategic investors, and a new approach to synthetic lethality that could expand the cancer-killing mechanism to a broad range of tumors.

The seed round announced on Wednesday was led by M Ventures, Novartis Venture Fund and Omega Funds. Pfizer Ventures and Life Science Partners also participated.

FoRx Therapeutics AG was formed around the discovery by University of Geneva professors Thanos Halazonetis and

Read the full 771 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers